Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway

Forensic Science International

Volumn 219, Issue 1-3, 2012, Pages 1-11

  Vindenes, Vigdis ^a   Jordbru, Dag ^b   Knapskog, Arne Birger ^c   Kvan, Elena ^d   Mathisrud, Grete ^e   Slørdal, Lars ^f,g   Mørland, Jørg ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b Norwegian Medicines Agency   (Norway)

^c Norwegian Directorate for Health   (Norway)

^d VESTRE VIKEN HOSPITAL TRUST   (Norway)

^e Department of Public Roads and Traffic Safety   (Norway)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Accident risk; Driving; Drug; DUI; Impaired; Legislative limits

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; ALPRAZOLAM; AMPHETAMINE; BUPRENORPHINE; CENTRAL STIMULANT AGENT; CLONAZEPAM; COCAINE; DIAZEPAM; DRONABINOL; FLUNITRAZEPAM; KETAMINE; LYSERGIDE; METHADONE; METHAMPHETAMINE; MORPHINE; NITRAZEPAM; OXAZEPAM; PHENAZEPAM; ZOLPIDEM; ZOPICLONE;

ALCOHOL BLOOD LEVEL; ALERTNESS; ATTENTION; CAR DRIVING; DECISION MAKING; DROWSINESS; DRUG BLOOD LEVEL; DRUG POTENCY; DRUNKEN DRIVING; LAW; MOTOR COORDINATION; NORWAY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEDATION; TRAFFIC ACCIDENT;

EID: 84861572306     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2011.11.004     Document Type: Review

References (138)

1. Jones A.W. Driving under the influence of drugs in Sweden with zero concentration limits in blood for controlled substances. Traffic Inj. Prev. 2005, 6:317-322.
2. Walsh J.M., de Gier J.J., Christopherson A.S., Verstraete A.G. Drugs and driving. Traffic Inj. Prev. 2004, 5:241-253.
3. Strand M., Fjeld B., Arnestad M., Mørland J. Psychomotor relevant performance: after single dose administration of opioids, narcoanalgesics and hallucinogens to drug naive subjects 2010, DRUID.
4. Barker M.J., Greenwood K.M., Jackson M., Crowe S.F. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004, 18:37-48.
5. Lucki I., Rickels K., Geller A.M. Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology (Berl.) 1986, 88:426-433.
6. Bradley C.M., Nicholson A.N. Effects of a mu-opioid receptor agonist (codeine phosphate) on visuo-motor coordination and dynamic visual acuity in man. Br. J. Clin. Pharmacol. 1986, 22:507-512.
7. Linnoila M., Mattila M.J. Interaction of alcohol and drugs on psychomotor skills as demonstrated by a driving simulator. Br. J. Pharmacol. 1973, 47:671P-672P.
8. Linnoila M., Hakkinen S. Effects of diazepam and codeine, alone and in combination with alcohol, on simulated driving. Clin. Pharmacol. Ther. 1974, 15:368-373.
9. Pickering G., Estrade M., Dubray C. Comparative trial of tramadol/paracetamol and codeine/paracetamol combination tablets on the vigilance of healthy volunteers. Fundam. Clin. Pharmacol. 2005, 19:707-711.
10. Evans W.O., Witt N.F. The interaction of high altitude and psychotropic drug action. Psychopharmacologia 1966, 10:184-188.
11. Ray W.A., Thapa P.B., Shorr R.I. Medications and the older driver. Clin. Geriatr. Med. 1993, 9:413-438.
12. Engeland A., Skurtveit S., Morland J. Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann. Epidemiol. 2007, 17:597-602.
13. Bachs L.C., Engeland A., Morland J.G., Skurtveit S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. Clin. Pharmacol. Ther. 2009, 85:596-599.
14. Gibson J.E., Hubbard R.B., Smith C.J., Tata L.J., Britton J.R., Fogarty A.W. Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes. Am. J. Epidemiol. 2009, 169:761-768.
15. Leveille S.G., Buchner D.M., Koepsell T.D., McCloskey L.W., Wolf M.E., Wagner E.H. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 1994, 5:591-598.
16. Movig K.L., Mathijssen M.P., Nagel P.H., van E.T., de Gier J.J., Leufkens H.G., Egberts A.C. Psychoactive substance use and the risk of motor vehicle accidents. Accid. Anal. Prev. 2004, 36:631-636.
17. Mura P., Kintz P., Ludes B., Gaulier J.M., Marquet P., Martin-Dupont S., Vincent F., Kaddour A., Goulle J.P., Nouveau J., Moulsma M., Tilhet-Coartet S., Pourrat O. Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects: results of a French collaborative study. Forensic Sci. Int. 2003, 133:79-85.
18. Drummer O.H., Gerostamoulos J., Batziris H., Chu M., Caplehorn J., Robertson M.D., Swann P. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid. Anal. Prev. 2004, 36:239-248.
19. Gustavsen I., Bramness J.G., Skurtveit S., Engeland A., Neutel I., Morland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med. 2008, 9:818-822.
20. Longo M.C., Hunter C.E., Lokan R.J., White J.M., White M.A. The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: part ii: the relationship between drug prevalence and drug concentration, and driver culpability. Accid. Anal. Prev. 2000, 32:623-632.
21. Laumon B., Gadegbeku B., Martin J.L., Biecheler M.B. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ 2005, 331:1371.
22. Blows S., Ivers R.Q., Connor J., Ameratunga S., Woodward M., Norton R. Marijuana use and car crash injury. Addiction 2005, 100:605-611.
23. Neutel C.I. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann. Epidemiol. 1995, 5:239-244.
24. Barbone F., McMahon A.D., Davey P.G., Morris A.D., Reid I.C., McDevitt D.G., MacDonald T.M. Association of road-traffic accidents with benzodiazepine use. Lancet 1998, 352:1331-1336.
25. Skegg D.C., Richards S.M., Doll R. Minor tranquillisers and road accidents. Br. Med. J. 1979, 1:917-919.
26. Honkanen R., Ertama L., Linnoila M., Alha A., Lukkari I., Karlsson M., Kiviluoto O., Puro M. Role of drugs in traffic accidents. Br. Med. J. 1980, 281:1309-1312.
27. Hemmelgarn B., Suissa S., Huang A., Boivin J.F., Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997, 278:27-31.
28. Woratanarat P., Ingsathit A., Suriyawongpaisal P., Rattanasiri S., Chatchaipun P., Wattayakorn K., Anukarahanonta T. Alcohol, illicit and non-illicit psychoactive drug use and road traffic injury in Thailand: a case-control study. Accid. Anal. Prev. 2009, 41:651-657.
29. Currie D., Hashemi K., Fothergill J., Findlay A., Harris A., Hindmarch I. The use of anti-depressants and benzodiazepines in the perpetrators and victims of accidents. Occup. Med. (Lond.) 1995, 45:323-325.
30. Bramness J.G., Skurtveit S., Morland J., Engeland A. The risk of traffic accidents after prescriptions of carisoprodol. Accid. Anal. Prev. 2007, 39:1050-1055.
31. Bramness J.G., Skurtveit S., Neutel C.I., Morland J., Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants: a study of population registry data in Norway. J. Clin. Psychiatry 2008, 69:1099-1103.
32. The relationship between drivers' blood alcohol concentration (BAC) and actual driving performance during high speed travel. Proceedings of the 10th International Conference on Alcohol, Drugs and Traffic Safety, vol. 87 1987, Excerpta Medica, Amsterdam. P.C. Noordzij, R. Roszbach (Eds.).
33. Drummer O.H. Benzodiazepines-effects on human performance and behavior. Forensic Sci. Rev. 2002, 14:2-14.
34. Shader R.I., Greenblatt D.J. Can you provide a table of equivalences for benzodiazepines and other marketed benzodiazepine receptor agonists?. J. Clin. Psychopharmacol. 1997, 17:331.
35. C.H. Ashton, Benzodiazepine equivalence table, 2007. http://www.benzo.org.uk/.
36. Verster J.C., Volkerts E.R., Verbaten M.N. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study. Neuropsychopharmacology 2002, 27:260-269.
37. Leufkens T.R., Vermeeren A., Smink B.E., van R.P., Ramaekers J.G. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1mg. Psychopharmacology (Berl.) 2007, 191:951-959.
38. Linnoila M., Stapleton J.M., Lister R., Moss H., Lane E., Granger A., Eckardt M.J. Effects of single doses of alprazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. Eur. J. Clin. Pharmacol. 1990, 39:21-28.
39. Bond A., Silveira J.C., Lader M. Effects of single doses of alprazolam and alcohol alone and in combination on psychological performance. Hum. psychopharmacol. 1991, 6:219-228.
40. dos Santos F.M., Goncalves J.C., Caminha R., da Silveira G.E., Neves C.S., Gram K.R., Ferreira C.T., Jacqmin P., Noel F. Pharmacokinetic/pharmacodynamic modeling of psychomotor impairment induced by oral clonazepam in healthy volunteers. Ther. Drug Monit. 2009, 31:566-574.
41. Ellinwood E.H., Nikaido A.M., Gupta S.K., Heatherly D.G., Hege S. Comparison of the relationship between structure and CNS effects for lorazepam, clonazepam and alprazolam. J. Psychopharmacol. (Oxf.) 1993, 7:24-32.
42. Ingum J., Bjorklund R., Bjorneboe A., Christophersen A.S., Dahlin E., Morland J. Relationship between drug plasma concentrations and psychomotor performance after single doses of ethanol and benzodiazepines. Psychopharmacology (Berl.) 1992, 107:11-17.
43. Haffner J.F., Morland J., Setekleiv J., Stromsaether C.E., Danielsen A., Frivik P.T., Dybing F. Mental and psychomotor effects of diazepam and ethanol. Acta Pharmacol. Toxicol. (Copenh.) 1973, 32:161-178.
44. Morland J., Setekleiv J., Haffner J.F., Stromsaether C.E., Danielsen A., Wethe G.H. Combined effects of diazepam and ethanol on mental and psychomotor functions. Acta Pharmacol. Toxicol. (Copenh.) 1974, 34:5-15.
45. Jalava K.M., Mattila M.J., Tarssanen M., Vanakoski J. Lorazepam and diazepam differently impair divided attention. Pharmacol. Biochem. Behav. 1995, 51:189-197.
46. Mattila M.J., Vanakoski J., Kalska H., Seppala T. Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol. Biochem. Behav. 1998, 59:917-923.
47. Vanakoski J., Mattila M.J., Seppala T. Driving under light and dark conditions: effects of alcohol and diazepam in young and older subjects. Eur. J. Clin. Pharmacol. 2000, 56:453-458.
48. Uvarova L.G., Zherdev V.P., Neznamov G.G., Khrulenko-Varnitskii I.O., Sigunova E.A. Correlation of the clinical pharmacological action of a single dose of fenazepam with the EEG dynamics and pharmacokinetics. Farmakol. Toksikol. 1986, 49:66-69.
49. Mrozkowska J., Vinge E., Borna C. Abuse of phenazepam-new phenomenon in Sweden benzodiazepine derivative from Russia caused severe intoxication. Lakartidningen 2009, 106:516-517.
50. Zherdev V.P., Caccia S., Garattini S., Ekonomov A.L. Species differences in phenazepam kinetics and metabolism. Eur. J. Drug Metab. Pharmacokinet. 1982, 7:191-196.
51. Vermeeren A., O'Hanlon J.F., Declerck A.C., Kho L. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther. 1995, 21:47-62.
52. O'Hanlon J.F., Volkerts E.R. Hypnotics and actual driving performance. Acta Psychiatr. Scand. Suppl. 1986, 332:95-104.
53. Seppala T., Nuotto E., Dreyfus J.F. Drug-alcohol interactions on psychomotor skills: zopiclone and flunitrazepam. Int. Pharmacopsychiatry 1982, 17(Suppl. 2):127-135.
54. Linnoila M., Erwin C.W., Brendle A., Logue P. Effects of alcohol and flunitrazepam on mood and performance in healthy young men. J. Clin. Pharmacol. 1981, 21:430-435.
55. Abanades S., Farre M., Barral D., Torrens M., Closas N., Langohr K., Pastor A., de la Torre R. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J. Clin. Psychopharmacol. 2007, 27:625-638.
56. Taberner P.V., Roberts C.J., Shrosbree E., Pycock C.J., English L. An investigation into the interaction between ethanol at low doses and the benzodiazepines nitrazepam and temazepam on psychomotor performance in normal subjects. Psychopharmacology (Berl.) 1983, 81:321-326.
57. Tedeschi G., Griffiths A.N., Smith A.T., Richens A. The effect of repeated doses of temazepam and nitrazepam on human psychomotor performance. Br. J. Clin. Pharmacol. 1985, 20:361-367.
58. Volkerts E.R., van Laar M.W., van Willigenburg A.P.P., Plomp T.A., Maes R.A.A. A comparative study of on-the-road and simulated driving performance after nocturnal treatment with lorazepam 1mg and oxazepam 50mg. Human psychopharmacology 1992, 7:297-309.
59. Verster J.C., Volkerts E.R., Schreuder A.H., Eijken E.J., van Heuckelum J.H., Veldhuijzen D.S., Verbaten M.N., Paty I., Darwish M., Danjou P., Patat A. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J. Clin. Psychopharmacol. 2002, 22:576-583.
60. Wilkinson C.J. The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. J. Clin. Psychiatry 1995, 56:309-318.
61. Leufkens T.R., Vermeeren A. Highway driving in the elderly the morning after bedtime use of hypnotics: a comparison between temazepam 20mg, zopiclone 7.5mg, and placebo. J. Clin. Psychopharmacol. 2009, 29:432-438.
62. Vermeeren A., Riedel W.J., van Boxtel M.P., Darwish M., Paty I., Patat A. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002, 25:224-231.
63. I. Gustavsen, K. Hjelmeland, J.P. Bernard, J. Morland, Individual psychomotor impairment in relation to zopiclone and ethanol concentrations in blood-a randomized controlled double-blinded trial. Addiction (2011), Oct 18. [Epub ahead of print]. doi:10.1111/j.1360-0443.2011.03693.x.
64. Kuitunen T., Mattila M.J., Seppala T. Actions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam and alcohol. Int. Clin. Psychopharmacol. 1990, 5(Suppl. 2):115-130.
65. Huestis M.A. Cannabis (Marijuana)-effects on human behavior and performance. Forensic Sci. Rev. 2002, 14:15-60.
66. Robbe H.W.J., O'Hanlon J.F. Marijuana and Actual Driving Performance 1993, National Highway Traffic Safety Administration, US Department of Transportation, Washington, DC.
67. Ramaekers J.G., Robbe H.W., O'Hanlon F.J. Marijuana, alcohol and actual driving performance. Hum. Psychopharmacol. 2000, 15:551-558.
68. Lenne M.G., Dietze P.M., Triggs T.J., Walmsley S., Murphy B., Redman J.R. The effects of cannabis and alcohol on simulated arterial driving: influences of driving experience and task demand. Accid. Anal. Prev. 2010, 42:859-866.
69. H.W.J. Robbe, Marijuana's effects on actual driving performance, 2008.
70. Ronen A., Gershon P., Drobiner H., Rabinovich A., Bar-Hamburger R., Mechoulam R., Cassuto Y., Shinar D. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid. Anal. Prev. 2008, 40:926-934.
71. The contribution of alcohol and other drugs among fatally injured drivers in Quebec: some preliminary results. Proceedings of the 16th International conference on Alcohol, Drugs and Traffic Safety on CD-ROM 2002.
72. Gjerde H., Normann P.T., Christophersen A.S., Samuelsen S.O., Morland J. Alcohol, psychoactive drugs and fatal road traffic accidents in Norway: a case-control study. Accid. Anal. Prev. 2011, 43:1197-1203.
73. Terhune K.W., Ippolito C.A., Hendrics D.L., Michalovic J.G., Bogema S.C., Santinga P., Blomberg R., Preusser D.F. The incidence and Role of Drugs in Fatally Injured Drivers. DOT HS-808 065 1992, National Highway Traffic Safety Administration, Washington.
74. Logan B.K. Methamphetamine and driving impairment. J. Forensic Sci. 1996, 41:457-464.
75. Logan B.K. Methamphetamine-effect on human performance and behaviour. Forensic Sci. Rev. 2002, 14:133-151.
76. Hollister L.E., Gillespie H.K. Marihuana, ethanol, and dextroamphetamine. Mood and mental function alterations. Arch. Gen. Psychiatry 1970, 23:199-203.
77. Perez-Reyes M., White W.R., McDonald S.A., Hicks R.E. Interaction between ethanol and dextroamphetamine: effects on psychomotor performance. Alcohol. Clin. Exp. Res. 1992, 16:75-81.
78. Asghar S.J., Tanay V.A., Baker G.B., Greenshaw A., Silverstone P.H. Relationship of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in healthy volunteers. Hum. Psychopharmacol. 2003, 18:291-299.
79. Silber B.Y., Croft R.J., Papafotiou K., Stough C. The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology (Berl.) 2006, 187:154-169.
80. Ramaekers J.G., Kuypers K.P., Samyn N. Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75mg and methylphenidate 20mg on actual driving during intoxication and withdrawal. Addiction 2006, 101:1614-1621.
81. Kuypers K.P., Samyn N., Ramaekers J.G. MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function. Psychopharmacology (Berl.) 2006, 187:467-475.
82. Silber B.Y., Papafotiou K., Croft R.J., Ogden E., Swann P., Stough C. The effects of dexamphetamine on simulated driving performance. Psychopharmacology (Berl.) 2005, 179:536-543.
83. Vollenweider F.X., Maguire R.P., Leenders K.L., Mathys K., Angst J. Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res. 1998, 83:149-162.
84. Gustavsen I., Morland J., Bramness J.G. Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers. Accid. Anal. Prev. 2006, 38:490-495.
85. Jones A.W. Age- and gender-related differences in blood amphetamine concentrations in apprehended drivers: lack of association with clinical evidence of impairment. Addiction 2007, 102:1085-1091.
86. Logan B.K. Amphetamines: an update on forensic issues. J. Anal. Toxicol. 2001, 25:400-404.
87. Drasbek K.R., Christensen J., Jensen K. Gamma-hydroxybutyrate-a drug of abuse. Acta Neurol. Scand. 2006, 114:145-156.
88. Nicholson K.L., Balster R.L. GHB: a new and novel drug of abuse. Drug Alcohol Depend. 2001, 63:1-22.
89. King L.A., Nutt D. Seizures in a night club. Lancet 2007, 370:220.
90. Gable R.S. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 2004, 99:686-696.
91. Al-Samarraie M.S., Karinen R., Morland J., Stokke O.M. Blood GHB concentrations and results of medical examinations in 25 car drivers in Norway. Eur. J. Clin. Pharmacol. 2010, 66:987-998.
92. Jones A.W., Holmgren A., Kugelberg F.C. Driving under the influence of gamma-hydroxybutyrate (GHB). Forensic Sci. Med. Pathol. 2008, 4:205-211.
93. Bosman I.J., Lusthof K.J. Forensic cases involving the use of GHB in The Netherlands. Forensic Sci. Int. 2003, 133:17-21.
94. Krystal J.H., Karper L.P., Bennett A., D'Souza D.C., Abi-Dargham A., Morrissey K., Abi-Saab D., Bremner J.D., Bowers M.B., Suckow R.F., Stetson P., Heninger G.R., Charney D.S. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl.) 1998, 135:213-229.
95. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Cappiello A., Krystal J.H. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch. Gen. Psychiatry 2000, 57:270-276.
96. Ghoneim M.M., Hinrichs J.V., Mewaldt S.P., Petersen R.C. Ketamine: behavioral effects of subanesthetic doses. J. Clin. Psychopharmacol. 1985, 5:70-77.
97. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
98. Aghajanian G.K., B.I.N.G.O.H. Persistence of lysergic acid diethylamide in the plasma of human subjects. Clin. Pharmacol. Ther. 1964, 5:611-614.
99. J.G. Bramness, S. Skurtveit, J. Mørland, A. Engeland, An increased risk of road traffic accidents after prescription of methadone, 2010.
100. Bourke D.L., Rosenberg M., Allen P.D. Physostigmine: effectiveness as an antagonist of respiratory depression and psychomotor effects caused by morphine or diazepam. Anesthesiology 1984, 61:523-528.
101. Th. Daldrup, J.J. deGier, K.J. Lusthof, J.G. Ramaekers, B.E. Smink, D.R.A. Uges, J.C. Verster, A.G. Verstraete, Advies grenswaarden voor drugs. In het kader van de voorgenomen wetswijziging van de Wegenverkeerswet, 1994, 31-3-2010.
102. Bramness J.G., Skurtveit S., Morland J. Clinical impairment of benzodiazepines-relation between benzodiazepine concentrations and impairment in apprehended drivers. Drug Alcohol Depend. 2002, 68:131-141.
103. Bramness J.G., Skurtveit S., Morland J. Testing for benzodiazepine inebriation-relationship between benzodiazepine concentration and simple clinical tests for impairment in a sample of drugged drivers. Eur. J. Clin. Pharmacol. 2003, 59:593-601.
104. Bramness J.G., Skurtveit S., Morland J. Flunitrazepam: psychomotor impairment, agitation and paradoxical reactions. Forensic Sci. Int. 2006, 159:83-91.
105. Bramness J.G., Khiabani H.Z., Morland J. Impairment due to cannabis and ethanol: clinical signs and additive effects. Addiction 2010, 105:1080-1087.
106. Gustavsen I., Al-Sammurraie M., Morland J., Bramness J.G. Impairment related to blood drug concentrations of zopiclone and zolpidem compared to alcohol in apprehended drivers. Accid. Anal. Prev. 2009, 41:462-466.
107. Khiabani H.Z., Bramness J.G., Bjorneboe A., Morland J. Relationship between THC concentration in blood and impairment in apprehended drivers. Traffic Inj. Prev. 2006, 7:111-116.
108. Bernard J.P., Morland J., Krogh M., Khiabani H.Z. Methadone and impairment in apprehended drivers. Addiction 2009, 104:457-464.
109. Bachs L., Hoiseth G., Skurtveit S., Morland J. Heroin-using drivers: importance of morphine and morphine-6-glucuronide on late clinical impairment. Eur. J. Clin. Pharmacol. 2006, 62:905-912.
110. Scavone J.M., Greenblatt D.J., Goddard J.E., Friedman H., Harmatz J.S., Shader R.I. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state. Eur. J. Clin. Pharmacol. 1992, 42:439-443.
111. R.C. Baselt (Ed.), Disposition of toxic drugs and chemicals in man, Eighth ed, 2008.
112. Jensen K.M. Determination of nitrazepam in serum by gas-liquid chromatography. Application in bioavailability studies. J. Chromatogr. 1975, 111:389-396.
113. Greenblatt D.J., Divoll M., Harmatz J.S., Shader R.I. Oxazepam kinetics: effects of age and sex. J. Pharmacol. Exp. Ther. 1980, 215:86-91.
114. Ochs H.R., Greenblatt D.J., Otten H. Disposition of oxazepam in relation to age, sex, and cigarette smoking. Klin. Wochenschr. 1981, 59:899-903.
115. Greenblatt D.J. Clinical pharmacokinetics of oxazepam and lorazepam. Clin. Pharmacokinet. 1981, 6:89-105.
116. Alvan G., Siwers B., Vessman J. Pharmacokinetics of oxazepam in healthy volunteers. Acta Pharmacol. Toxicol. (Copenh) 1977, 40(Suppl 1):40-51.
117. Salva P., Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin. Pharmacokinet. 1995, 29:142-153.
118. Rush C.R., Baker R.W., Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology (Berl) 1999, 144:220-233.
119. Fernandez C., Martin C., Gimenez F., Farinotti R. Clinical pharmacokinetics of zopiclone. Clin. Pharmacokinet. 1995, 29:431-441.
120. Cimolai N. Zopiclone: is it a pharmacologic agent for abuse?. Can. Fam. Physician. 2007, 53:2124-2129.
121. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 2003, 42:327-360.
122. Fahren unter Drogen-oder Medikamenteninfluss. Forensische interpretation und begutachtung 1994, Institut fur Rechtsmedizin der Universitat Zurich. P.F. Iten (Ed.).
123. Pizarro N., Ortuno J., Segura J., Farre M., Mas M., Cami J., et al. Quantification of amphetamine plasma concentrations by gas chromatography coupled to mass spectrometry. J. Pharm. Biomed. Anal. 1999, 21:739-747.
124. Angrist B., Corwin J., Bartlik B., Cooper T. Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biol. Psychiatry. 1987, 22:1357-1368.
125. Wilkinson P., Van D.C., Jatlow P., Barash P., Byck R. Intranasal and oral cocaine kinetics. Clin. Pharmacol. Ther. 1980, 27:386-394.
126. Collins S.L., Evans S.M., Foltin R.W., Haney M. Intranasal cocaine in humans: effects of sex and menstrual cycle. Pharmacol. Biochem. Behav. 2007, 86:117-124.
127. Kolbrich E.A., Goodwin R.S., Gorelick D.A., Hayes R.J., Stein E.A., Huestis M.A. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther. Drug. Monit. 2008, 30:320-332.
128. de la Torre R., Farre M., Mathuna B.O., Roset P.N., Pizarro N., Segura M., et al. MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur. J. Clin. Pharmacol. 2005, 61:551-554.
129. de la Torre R., Farre M., Ortuno J., Mas M., Brenneisen R., Roset P.N., et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br. J. Clin. Pharmacol. 2000, 49:104-109.
130. Cruickshank C.C., Dyer K.R. A review of the clinical pharmacology of methamphetamine. Addiction 2009, 104:1085-1099.
131. Ferrara S.D., Zotti S., Tedeschi L., Frison G., Castagna F., Gallimberti L., et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br. J. Clin. Pharmacol. 1992, 34:231-235.
132. Scharf M.B., Lai A.A., Branigan B., Stover R., Berkowitz D.B. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 1998, 21:507-514.
133. Schmid R.L., Sandler A.N., Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999, 82:111-125.
134. Passie T., Halpern J.H., Stichtenoth D.O., Emrich H.M., Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci. Ther. 2008, 14:295-314.
135. Jensen M.L., Foster D.J., Upton R.N., Kristensen K., Hansen S.H., Jensen N.H., et al. Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers. Eur. J. Clin. Pharmacol. 2007, 63:1153-1159.
136. Meresaar U., Nilsson M.I., Holmstrand J., Anggard E. Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur. J. Clin. Pharmacol. 1981, 20:473-478.
137. Osborne R., Joel S., Trew D., Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin. Pharmacol. Ther. 1990, 47:12-19.
138. Dershwitz M., Walsh J.L., Morishige R.J., Connors P.M., Rubsamen R.M., Shafer S.L., et al. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology 2000, 93:619-628.